Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ZDHHC20P3 is classified as a pseudogene, i.e., a genomic DNA segment similar to a known gene but, due to mutations or lack of regulatory elements, is not expected to be transcribed and translated into a functional protein. While its functional parent gene (ZDHHC20) encodes a palmitoyltransferase enzyme involved in protein palmitoylation and has documented roles in cancer biology and antiviral responses[1][2][3], ZDHHC20P3 itself does not have any known biological activity, therapeutic relevance, or mechanistic roles. There are no known interacting drugs, biomarker uses, or clinical safety concerns associated with this pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on zinc finger DHHC-type containing 20 pseudogene 3 (ZDHHC20P3).